Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.26M Sell
30,697
-11,933
-28% -$2.37M 2.47% 19
2026
Q1
$6.28M Sell
42,630
-7,890
-16% -$1.15M 3.01% 14
2025
Q4
$6.14M Buy
50,520
+13,310
+36% +$1.56M 2.19% 17
2025
Q3
$4.01M Buy
37,210
+5,440
+17% +$508K 1.47% 26
2025
Q2
$2.85M Buy
+31,770
New +$2.39M 1.13% 31
2025
Q1
Sell
-35,770
Closed -$2.25M 69
2024
Q4
$2.25M Sell
35,770
-22,130
-38% -$1.5M 0.91% 30
2024
Q3
$4.48M Sell
57,900
-16,640
-22% -$1.31M 1.94% 18
2024
Q2
$6.15M Buy
74,540
+790
+1% +$58.4K 2.53% 15
2024
Q1
$5.15M Buy
73,750
+310
+0.4% +$19.9K 2.27% 16
2023
Q4
$4.27M Sell
73,440
-4,530
-6% -$236K 2.36% 14
2023
Q3
$3.58M Buy
77,970
+23,620
+43% +$1.13M 2.37% 19
2023
Q2
$2.64M Buy
+54,350
New +$2.27M 1.72% 22

Other funds holding KLAC

Geneva Partners's KLAC Position: Q2 2026 in Review

Geneva Partners reduced its KLA (KLAC) stake by 28% in Q2 2026, selling an estimated $2.37M and leaving 30,697 shares worth $9.26M. The position accounts for 2.47% of the portfolio, ranked #19.

Geneva Partners first reported a position in KLAC in Q2 2023 and has held it in 12 quarters since. 2,477 funds tracked by Wall St. Rank hold KLAC as of Q2 2026.

  • Geneva Partners held 30,697 shares of KLA worth $9.26M as of Q2 2026.
  • Geneva Partners sold 11,933 KLA shares in Q2 2026, an estimated $2.37M.
  • KLA made up 2.47% of Geneva Partners's portfolio in Q2 2026, its #19 holding.
  • Geneva Partners first reported a position in KLA in Q2 2023 and has held it in 12 quarters since.
  • 2,477 funds tracked by Wall St. Rank held KLA as of Q2 2026.

Based on Geneva Partners's 13F filing for Q2 2026, filed 10 Aug 2026.